Payment overview · 2025
General Payments
$1,515.52
16 reported records · 13 companies
Healthcare provider profile · identity verified
Wei Luo
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Adult Health · ANN ARBOR, MI · NPI 1528659836
Verified facts
What the public records show
CMS Open Payments records show Wei Luo received $1,515.52 in general payments during 2025 across 16 reported records.
Amgen Inc. accounted for 16.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 236 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $243.92 | 16.1% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $234.23 | 15.5% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $124.99 | 8.2% | 1 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $122.06 | 8.1% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $122.06 | 8.1% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $115.64 | 7.6% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$112.18 | 7.4% | 1 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $100.80 | 6.7% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $95.04 | 6.3% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $92.92 | 6.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $67.59 | 4.5% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $49.02 | 3.2% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $35.07 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,515.52 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BENLYSTA Normalized: benlysta |
Biological | GlaxoSmithKline, LLC. | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $122.06 | 1 | 2025 |
Source payment records
|
|||||
| Epclusa Normalized: epclusa |
Drug | Gilead Sciences, Inc. | $121.85 | 1 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $118.93 | 1 | 2025 |
Source payment records
|
|||||
| CERDELGA Normalized: cerdelga |
Drug | GENZYME CORPORATION | $115.64 | 1 | 2025 |
Source payment records
|
|||||
| CEREZYME Normalized: cerezyme |
Biological | GENZYME CORPORATION | $115.64 | 1 | 2025 |
Source payment records
|
|||||
| Yeztugo Normalized: yeztugo |
Drug | Gilead Sciences, Inc. | $112.38 | 1 | 2025 |
Source payment records
|
|||||
| INTERSTIM Normalized: interstim |
Device | Medtronic, Inc. | $112.18 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka Pharmaceutical Development & Commercialization, Inc. | $100.80 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $95.04 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $92.92 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $67.59 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $67.59 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $49.02 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $35.07 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
236 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 322 | 60 |
| Gabapentin | Gabapentin | 246 | 59 |
| Eliquis | Apixaban | 236 | 25 |
| Levothyroxine Sodium | Levothyroxine Sodium | 182 | 35 |
| Amlodipine Besylate | Amlodipine Besylate | 138 | 28 |
| Potassium Chloride | Potassium Chloride | 137 | 30 |
| Sertraline Hcl | Sertraline Hcl | 137 | 24 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 132 | 34 |
| Furosemide | Furosemide | 117 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 97 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 91 | 24 |
| Trazodone Hcl | Trazodone Hcl | 90 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 83 | suppressed |
| Lisinopril | Lisinopril | 83 | 24 |
| Baclofen | Baclofen | 82 | 18 |
| Metformin Hcl | Metformin Hcl | 75 | 18 |
| Buspirone Hcl | Buspirone Hcl | 72 | 12 |
| Atenolol | Atenolol | 66 | suppressed |
| Mirtazapine | Mirtazapine | 63 | 14 |
| Levetiracetam | Levetiracetam | 62 | 11 |
| Tramadol Hcl | Tramadol Hcl | 60 | 18 |
| Divalproex Sodium | Divalproex Sodium | 55 | 15 |
| Lorazepam | Lorazepam | 54 | 23 |
| Losartan Potassium | Losartan Potassium | 54 | 20 |
| Methocarbamol | Methocarbamol | 52 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 52 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 50 | 21 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 49 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 48 | suppressed |
| Clonazepam | Clonazepam | 45 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 44 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 43 | suppressed |
| Simvastatin | Simvastatin | 42 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 42 | suppressed |
| Januvia | Sitagliptin Phosphate | 41 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 40 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 40 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 37 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 35 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 32 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 32 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 31 | suppressed |
| Carvedilol | Carvedilol | 31 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 31 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 30 | 13 |
| Restasis | Cyclosporine | 30 | suppressed |
| Xarelto | Rivaroxaban | 30 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Humalog | Insulin Lispro | 29 | suppressed |
| Levofloxacin | Levofloxacin | 29 | 22 |
| Pregabalin | Pregabalin | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 13 |
| Lacosamide | Lacosamide | 28 | 11 |
| Memantine Hcl | Memantine Hcl | 28 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 28 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 27 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 14 |
| Tradjenta | Linagliptin | 26 | suppressed |
| Jardiance | Empagliflozin | 25 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 25 | 12 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Bumetanide | Bumetanide | 24 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Enulose | Lactulose | 23 | suppressed |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Azithromycin | Azithromycin | 22 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | 12 |
| Allopurinol | Allopurinol | 21 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Glipizide | Glipizide | 21 | suppressed |
| Olanzapine | Olanzapine | 21 | suppressed |
| Alprazolam | Alprazolam | 19 | suppressed |
| Clonidine | Clonidine | 19 | suppressed |
| Humulin R | Insulin Regular, Human | 19 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Rivastigmine | Rivastigmine | 18 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 17 | 17 |
| Latanoprost | Latanoprost | 17 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 16 | suppressed |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 14 | 14 |
| Cephalexin | Cephalexin | 14 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 11 |
| Fosfomycin Tromethamine | Fosfomycin Tromethamine | 14 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 14 | suppressed |
| Prednisone | Prednisone | 14 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Letrozole | Letrozole | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 13 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 11 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Omeprazole | Omeprazole | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,515.52 · 16 records | Amgen Inc. | Auvelity, BENLYSTA, CERDELGA, CEREZYME, Dexcom G6 Transmitter, EVENITY, Epclusa, INGREZZA, INTERSTIM, Korlym, NURTEC ODT, REXULTI, TEPEZZA, UZEDY, Yeztugo, ZAVZPRET | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error